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Introduction
Cancer immunotherapy has progressed dramati-
cally after the introduction of immune checkpoint 
inhibitors (ICI), which include antagonistic anti-
bodies that block key co-inhibitory molecules, 
including cytotoxic T lymphocyte antigen 4 
(CTLA-4), programmed cell death protein 
(PD-1) and programmed death-ligand 1 (PD-
L1), all of which are overexpressed in certain 
tumour microenvironments. Targeting CTLA-4, 
PD-1 and PD-L1 reactivates cytotoxic T lympho-
cytes, allowing the immune system to destroy 
cancer cells.
The ICI currently in use are ipilimumab (anti-
CTLA-4), nivolumab, pembrolizumab (anti-PD-1), 
and atezolizumab, avelumab and durvalumab 
(anti-PD-L1), against a number of cancers 
including melanoma, renal cell carcinoma, blad-
der cancer, head and neck cancers and 
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Abstract
Background: Drug-induced colitis is a known complication of therapies that alter the immune 
balance, damage the intestinal barrier or disturb intestinal microbiota. Immune checkpoint 
inhibitors (ICI) directed against cancer cells may result in activated T lymphocyte-induced 
immune-related adverse events (AEs), including immune-related colitis and hepatitis. The aim 
of this review article is to summarize the incidence of gastrointestinal (GI) and hepatic AEs 
related to ICI therapy. We have also looked at the pathogenesis of immune-mediated AEs and 
propose management strategies based on current available evidence.
Methods: A literature search using PubMed and Medline databases was undertaken using 
relevant search terms pertaining to names of individual drugs, mechanism of action, related 
AEs and their management.
Results: ICI-related GI AEs are common, and colitis appears to be the most common side 
effect, with some studies reporting incidence as high as 30%. The incidence of both all-grade 
colitis and hepatitis were highest with combination therapy with anti-CTLA-4/PD-1; severity 
of colitis was dose-dependent (anti-CTLA-4). Early intervention is associated with better 
outcomes.
Conclusion: ICI-related GI and hepatic AEs are common and clinicians need to be aware. 
Patients with GI AEs benefit from early diagnosis using endoscopy and computed tomography. 
Early intervention with oral steroids is effective in the majority of patients, and in steroid-
refractory colitis infliximab and vedolizumab have been reported to be useful; mycophenolate 
has been used for steroid-refractory hepatitis.
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lung cancers. While ICIs reactivate cytotoxic 
T lymphocytes, allowing them to destroy cancer 
cells, it may also result in immune-related adverse 
events (IrAEs) in a proportion of patients as the 
reactivated T cells attack other tissues. The intes-
tine, especially the colon, appears to be one of the 
most common target organs for acute IrAEs,1 
with lymphocytic and neutrophilic inflammation 
and in some cases granuloma and crypt abscesses.2 
However, other AEs, including endocrine dys-
function, skin and mucosal manifestations, pol-
yarthritis, pneumonitis and haematologic 
disorders, also occur.
Most studies that have described and reported 
AEs related to ICI therapies include data from 
therapy with ipilimumab, pembrolizumab, 
nivolumab and atezolizumab. The spectrum of 
IrAEs induced by these drugs can be disabling 
and may lead to discontinuation of cancer immu-
notherapy. This narrative review focuses on 
immune-related colitis and hepatitis and their 
management, though involvement of other organs 
in IrAE may influence management strategies. 
Due to a lack of randomized studies on the topic, 
we have not conducted a systematic review.
Search strategy
A literature search using PubMed and Medline 
databases was undertaken first using the search 
terms ‘immune check point inhibitors’ or ‘check 
point inhibitors’; searches also included individ-
ual drugs ‘ipilimumab’ or ‘pembrolizumab’ or 
‘nivolumab’ or ‘atezolizumab’ or ‘avelumab’ and 
mechanism, that is ‘anti-CTLA-4’, ‘anti-PD-1’ 
or ‘anti-PD-L1’. These terms were then com-
bined with keywords ‘colitis’ or ‘immune medi-
ated colitis’ or ‘complications’, ‘side effects’ or 
‘adverse events’ or ‘gastrointestinal and hepatic 
adverse events’ and ‘management of adverse 
events’.
Gastrointestinal and hepatic AEs in 
checkpoint inhibitor therapy
Incidence of GI and hepatic AEs
The incidence of GI AEs appears to be dependent 
on various factors. A systematic review and meta-
analysis by Wang and colleagues, published in 
2017, looked at 34 studies with a total of 8863 
patients, and reported differences in incidence 
rates of colitis related to ICI therapy based on the 
type of therapy (single, combination), tumour type 
and the dosage of therapies used.3 The overall inci-
dence of all grades of colitis in their review was 
noted to be 2.4% (95% CI, 1.6–3.6%) and 1.7% 
(95% CI, 1.1–2.5%) for grade 3–4 colitis.3 The 
grading system used is as per the common termi-
nologies used in clinical trials as per guidance from 
the National Cancer Institute (see Table 1).4
A systematic review of IrAEs related to anti-PD1 
and anti-PD-L1 therapies showed a lower pro-
portion of colitis compared to patients on anti-
CTLA-4 therapy.5 Another comprehensive 
systematic review by Wang and colleagues, which 
focused on fatal toxic effects of all ICI therapies 
using the World Health Organization database, 
reported 613 fatal events from 2009 to January 
2018.6 Among these, 193 deaths were related to 
anti-CTLA-4 therapy, most commonly from coli-
tis [135 (70%)], whereas pneumonitis and hepa-
titis (22%) were more often the causes of death 
with anti-PD-1/PD-L1-related fatalities. With 
combination PD-1/CTLA-4 therapy, death was 
more frequently from colitis (37%) and myocar-
ditis (25%).6 Although the colon is most com-
monly affected, there have been reports of upper 
GI involvement. A case report of lymphocytic 
gastritis secondary to pembrolizumab therapy has 
recently been published.7
A detailed breakdown of incidence rates of GI 
and hepatic adverse events related to ICI therapy 
is provided in Table 2.
In some studies, approximately 30% of patients 
treated with anti-CTLA-4 antibodies were seen 
to develop diarrhoea, with about 10% having 
symptoms severe enough to consider interrup-
tion of therapy. Immune-related colitis is diag-
nosed in approximately 5% of patients.8,11 
Diarrhoea is less common with inhibition of 
PD-1 and PD-L1 (about 12% of patients develop 
diarrhoea and 2% severe diarrhoea), with 
immune-related colitis reported in 1–2% of 
cases.12 In one meta-analysis looking at risk of 
IrAEs of anti-PD-1 and anti-PD-L1 therapy, the 
authors concluded that anti-PD-1 therapy may 
result in a higher risk of all-grade immune-
related colitis when compared with chemo-
therapy.13 Also, pembrolizumab was noted to 
carry a higher risk of all-grade colitis compared 
to chemotherapy. This increased risk was more 
commonly seen in patients with non-small cell 
lung compared to malignant melanoma.
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They also noted that nivolumab and atezolizumab 
probably did not increase the risk of immune-
related colitis when compared with chemother-
apy. The reduced risk of all-grade colitis seen 
with nivolumab is unusual, considering that pem-
brolizumab and nivolumab have a similar mecha-
nism of action. This was also investigated by 
Fessas and colleagues, who reported on the 
molecular and preclinical comparisons between 
nivolumab and pembrolizumab.14 In this compre-
hensive study, they found significant molecular 
similarities between the two drugs and concluded 
that the differences in AEs seen in clinical trials 
may be due to drug-independent factors, such as 
differences in the patient populations in the trials.
An analysis of the AE profiles spontaneously 
reported to the US Food and Drug Administration 
Adverse Event Reporting System database 
showed that nivolumab and pembrolizumab have 
very similar safety profiles, but the signal strength 
of AEs increased when combined with ipili-
mumab.15 In addition, the quality of IrAE data-
reporting in clinical trials may be suboptimal,16 
and this may also account for subtle differences in 
reporting of different agents. Safety profiles of 
immunotherapies are also not similar for all 
tumour types.
The incidence of liver dysfunction (mainly hepa-
titis) caused by ICI therapy is much lower 
compared to diarrhoea, and is reported in about 
1–6% of patients, mostly at grades 1 and 2.8,9 In 
studies reporting hepatic dysfunction, deranged 
transaminases is the most common form of abnor-
mality. The median time to onset of liver dys-
function varied greatly with therapy and type of 
cancer. The details of differences in incidence of 
hepatitis among therapies10 is given in Table 2.
Pathogenesis
The cellular and molecular basis of IrAEs upon ICI 
therapy and the reason for predominance of GI 
toxicity is still not completely understood, but it 
might be because tumour neoantigens and normal 
tissue antigens of the GI tract are cross-reactive,17 
and microbial epitopes important for host protec-
tion to GI infection may overlap with tumour 
neoantigens.18
Under these conditions in the presence of ICI 
that block co-inhibitory pathways, activation and 
expansion of effector CD4+ and CD8+ T cells is 
favoured as co-stimulation signals that drive T 
cell glycolysis, proliferation and survival are sus-
tained. The mechanism might also involve deple-
tion of Treg numbers caused by antibody 
dependent cellular cytotoxicity (ADCC) or 
phagocytosis of antibody-marked Tregs by FcR-
expressing tissue macrophages.19,20 In the case of 
anti-PD-1/PD-L1 therapy, iTreg depletion might 
Table 1. The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), version 4.
Adverse effect Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Diarrhoea Increase of <4 stools 
per day over baseline; 
mild increase in 
ostomy output 
compared to baseline
Increase of 4–6 stools 
per day over baseline; 
moderate increase 
in ostomy output 
compared to baseline
Increase of 7 or more 
stools per day over 
baseline; incontinence; 
hospitalization indicated; 
severe increase in ostomy 
output compared to 
baseline; limiting self-
care ADL
Life-threatening 
consequences; 
urgent intervention 
indicated
Death
Colitis Asymptomatic; 
clinical or diagnostic 
observations only; 
intervention not 
indicated
Abdominal pain; 
mucus or blood in 
stool
Severe abdominal pain; 
change in bowel habits; 
medical intervention 
indicated; peritoneal signs
Life-threatening 
consequences; 
urgent intervention 
indicated
Death
Hepatitis AST or ALT 1–2.5× 
ULN and/or T-BIL 
1–1.5× ULN
AST or ALT 2.5–5× 
ULN and/or T-BIL 
1.5–3× ULN
AST or ALT >5× ULN and/
or T-BIL >3× ULN
AST or ALT >8× 
ULN
Death
The current version in use is CTCAE version 5 but all studies included in this study reported adverse events using CTCAE version 4. 
ADL, activities of daily living; T-BIL, total bilirubin; ULN, upper limit of normal.
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also be due to the role of PD-1 signalling in 
enhancing FoxP3 expression and the mainte-
nance of iTreg.21 The co-inhibitory pathways 
controlled by CTLA-4 and PD-1, and the mech-
anisms by which their blockade with antagonistic 
antibodies can lead to IrAEs and GI toxicity, are 
summarized in Figure 1 and described compre-
hensively in the respective legends.
The generally greater incidence and severity of 
IrAEs under anti-CTLA-4 therapy compared to 
ani-PD-1/PD-L1 therapies probably reflects the 
more dominant role of CTLA-4 as an inhibitor of 
T cell activation compared to PD-1, as it is the 
principal counter regulator of CD28, which deliv-
ers the primary co-stimulation signal. CTLA-4 is 
also induced more rapidly on activated T cells 
and constitutively expressed by a greater propor-
tion of Tregs than PD-1.22 Greater toxicity of 
anti-CTLA-4 therapy might also relate to the 
relative presence of ligands at areas of the body 
where maintenance of tolerance is most critical 
and is the consequence of losing inhibitory back 
signals in antigen-presenting cells (APCs).22,23
Overall, it appears that an inevitable consequence 
of targeting CTLA-4, PD-1 and PD-L1 is to reac-
tivate cytotoxic T cells to drive destruction of 
tumour cells in the tumour micro-environment 
where these immunosuppressive molecules are 
significantly overexpressed. Such a disturbance of 
the homeostasis of the immune system favours the 
development of IrAEs, especially in the colon. 
Tumour neoantigens, microbial epitopes and host 
susceptibility to GI toxicity all have a role to play. 
Diarrhoea is more common than colitis and it is 
likely that the former represents a milder, more 
microscopic involvement of the colon than the lat-
ter, which includes ulcerative changes, though this 
requires further study. Colitis shares some of the 
features of Crohn’s disease and the small bowel 
may be involved (with lymphocytic and neutro-
philic inflammation and in some cases granuloma 
and crypt abscesses).24 Recently, attention has 
focused on delayed immune-related events 
(DIREs) after discontinuation of immunotherapy, 
but these appear uncommon for GI toxicity and 
more common for endocrine, dermatologic or 
neurologic toxicities.25
Table 2. Incidence of gastrointestinal and hepatic adverse events.
Overall incidence
(all-grade colitis)
Grade 3–4  
colitis
Grade 3–4 
diarrhoea
Hepatitis
all grades
Hepatitis
Grade 3–4
Single-agent therapy
 Anti-CTLA-4 9.1% (6.6–12.5%)3 6.8% (5.3–8.6%) 7.9% (5.5–11.4%) 1.9% (0.9–3.9%)8  
 Anti-PD-1 1.4% (1.1–1.8%)3 0.9% (0.7–1.3%) 1.3% (1.0–1.7%) 1.2% (0.7–1.8%)9,10 1.1% (0.5–1.7%)
 Anti-PD-L1 1.0% (0.4–2.2%)3,5 0.6% (0.2–1.6%) 0.3% (0.1–1.1%) 1.5% (0.9–2.5%)9,10 0.8% (0.6–1.0%)
Combination therapy
  Anti-CTLA-4/PD-1 13.6% (7.7–22.9%)3 9.4% (4.8–17.4%) 9.2% (6.8–12.3%) 17.6%6 8.3%
Tumour type
  Melanoma 1.8%3 1.2% (0.8–1.7%) 1.4% 3.8% 1.3%
  Renal cell carcinoma 0.4%3 0.4% (0.1–1.8%) 1.0%  
  Non-small cell lung 
cancer
0.8% 0.5% (0.3–1.0%) 1.2%  
Dosage of therapies
  Ipilimumab (3 mg/kg) 9.6% (7.6–12.0%)8 7.1% (5.3–9.4%) 5.2% (3.3–8.2%)  
  Ipilimumab (10 mg/kg) 6.6% (2.4–16.75%)8 5.1% (2.5–9.9%) 11.5% (8.5–15.5%)  
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Figure 1. Pathology of checkpoint-inhibitor-induced gastrointestinal toxicities. In healthy tissues (A) low levels of self- or non-self-
antigen-TCR and CD28 co-stimulation signals that lead to increased glycolysis, T cell proliferation and survival are balanced by 
inhibitory signals through co-inhibitory receptors CTLA-4 and PD-1 that are constitutively expressed on patrolling Treg and induced 
on stimulated effector T cells. The inhibitory pathways that extend from these receptors include (a) competitive binding of CTLA-
4 and CD28 for their shared ligands CD80 and CD86 – this is enhanced by CD86/80 transendocytosis in which CTLA-4 recruits its 
ligands into vesicles that deliver them to the lysosome for degradation; (b) dephosphorylation of activatory phosphate groups on 
signalling proteins assembled downstream of CD28 and antigen-TCR; (c) production of kinurenins that inhibit T cell proliferation 
from tryptophan by indoleamine dioxygenase (IDO), which is activated downstream of CD86/80 engagement of CTLA-4; and (d) 
induction of FoxP3 downstream of PD-1.
In tumour (B), CTLA-4, PD-1 and their ligands are elevated. Inhibitory signals (a–d) are therefore increased relative to stimulatory 
signals through tumour neoantigen-TCR and CD28. This reduces the activation and expansion of effector T cells, enabling the 
tumour to grow.
Anti-CTLA-4 and anti-PD-1/PD-L1 therapies (C) block inhibitory pathways (a–d) and Treg with constitutively high expression of CTLA-
4 and PD-1 are destroyed by tissue macrophages through antibody dependent cellular cytotoxicity (ADCC) and antibody-mediated 
phagocytosis. Altogether this results in T cell activation, proliferation and survival and differentiation into inflammatory effector 
classes that mediate destruction of the tumour but promote IrAEs in peripheral tissues, especially the colon, where self-antigens or 
microbial antigens might overlap with tumour neoantigens.
Key: Green lines represent co-stimulation pathways and red lines co-inhibitory pathways. Arrowheads indicate induction and wedges inhibition of the 
response. Line thickness indicates the strength of the pathway.
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Diagnosis
Diagnosis of GI-related AEs
There is considerable variation in time to onset 
of colitis following anti-CTLA-4 therapy. Weber 
and colleagues reported that GI IrAEs were 
observed after a median of 8 weeks into treat-
ment in a phase III trial.26 In another study, 
patients developed immune-related enterocolitis 
after a median of 11 days (range, 0–59 days) from 
last dose of ipilimumab.27 In a pooled analysis, 
the median time to onset of GI IrAEs was 7 weeks 
for nivolumab and 18 weeks for pembrolizumab 
(for any grade of colitis).12,28 Any new onset of 
symptoms soon after commencing ICI therapy 
must prompt clinicians to consider and maintain 
a high index of suspicion of IrAEs until proven 
otherwise.
Investigations. In addition to routine blood tests, 
investigation of patients with ICI-related diar-
rhoea should first include stool tests to exclude 
enteric infections. Once ruled out, other tests 
should follow swiftly. The role of faecal calprotec-
tin as a diagnostic marker is still unclear. One 
study demonstrated that an elevated level com-
pared to baseline was not specific to patients 
reporting grade 2 or higher GI IrAEs.29
Endoscopy and its role. Endoscopy is an impor-
tant tool for diagnosis, and clinicians should have 
a low threshold to use it once ICI-related GI 
symptoms are reported by patients. A full colo-
noscopy is recommended as index procedure 
wherever possible. In one study, the authors 
noted that nearly 10% of patients had involve-
ment only in the right colon or terminal ileum.30 
They also noted that timing of endoscopy was an 
important factor affecting outcomes. The dura-
tion of steroid therapy, recurrence of symptoms, 
admission to intensive care and the need to use 
infliximab were all lower in patients who under-
went endoscopy within 30 days of onset of GI 
symptoms.30
Endoscopic features can vary widely, from a mac-
roscopically normal-looking mucosa to various 
degrees of mucosal ulcerations and erythema. 
Patients who have a normal endoscopy are likely 
to require a shorter course of steroids and less 
likely to go on infliximab.30 In a case series of 39 
patients with anti-CTLA-4-related enterocolitis, 
all patients underwent at least a sigmoidoscopy 
and 25 had a complete ileo-colonoscopy. Among 
these patients, nearly all had ulceration involving 
the rectum and sigmoid colon. It was noted that 
66% had extensive colitis and 20% had ileal 
involvement.31
Histological features of ICI-related colitis. There is 
some variation in histological features that have 
been observed. Although the features are gener-
ally similar in colitis resulting from all ICI thera-
pies, there are some minor differences with each.
In patients treated with anti-CTLA-4 therapy, 
most commonly seen features appear to be dense 
lymphocytic infiltration in the lamina propria 
with frequent presence of plasma cells and eosin-
ophils. Karamchandani and colleagues describe 
that in such patients features such as neutrophilic 
infiltration, neutrophilic cryptitis or crypt micro-
abscesses and increased crypt epithelial apoptosis 
are common (Figure 2).32
In another study, out of 90 colonic biopsies taken 
from patients with ICI-related colitis, the most 
common feature was an increase in lamina pro-
pria cellularity (83%) and the second most com-
mon feature was neutrophilic infiltration (79%).33 
Other notable features are increased intraepithe-
lial lymphocytes and absence of granulomas. It is 
worth mentioning that features of chronicity, for 
example basal plasmacytosis and architectural 
distortion, are usually absent (Figure 2).32
Although the histological features due to anti-
PD1 therapy tend to be similar, there have been 
some reports of granulomas being seen in biop-
sies and features of chronicity could be seen in 
recurrent colitis related to the drug.32,34
Overall, for most cases of ICI-related colitis, histo-
logic features resemble that of severe active ulcera-
tive colitis (UC), but no specific histologic pattern 
or feature has been identified. As compared to 
true UC, however, the crypt destruction and bal-
looning distention are more prominent, and fea-
tures of chronicity are less impressive, particularly 
with only minimal crypt architecture distortion. In 
addition, some cases also show marked apoptotic 
activity in cryptal epithelium, which is not a com-
mon feature of inflammatory bowel disease (IBD). 
It is worth noting, however, that IBD itself is a 
group of disorders with considerable heterogene-
ity, and although there are some features common 
to both IBD and ICI-related colitis, there is con-
siderable variation noted in this condition.
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Imaging. Cross-sectional imaging primarily in 
the form of computed tomography (CT) or mag-
netic resonance imaging is helpful to determine 
the extent of inflammation and exclude complica-
tions such as perforation. A CT scan should be 
considered when patients present with alarm 
symptoms like sudden-onset abdominal pain or 
features of sepsis. In a retrospective study of 
patients who developed ipilimumab-associated 
colitis, three predominant radiological patterns 
were observed on CT or positron emission 
tomography/CT studies. Isolated recto-sigmoid 
colitis without diverticulosis, diffuse colitis and 
segmental colitis associated with diverticulosis 
were observed in 50%, 33% and 17% of patients, 
respectively.35 In a study published in 2017, CT 
findings were found to be highly predictive of 
colitis on biopsy, with a positive predictive value 
of 96%.36 In symptomatic patients who had CT 
evaluation, CT was highly predictive of the need 
for steroids to reach resolution of symptoms, with 
a positive predictive value of 92%.36
Other CT findings, such as mesenteric vessel 
engorgement, bowel wall thickening and colonic 
distention could be seen (extensive or segmental); 
segmental findings could lead to a reported dif-
ferential diagnosis of diverticular sigmoiditis.37,38
Diagnosis of hepatic dysfunction. As previously 
mentioned, the most common form of hepatotox-
icity related to ICI therapy is hepatitis, defined by 
elevations in serum aminotransferases (ALT and 
AST) with or without change in bilirubin levels. 
Based on current available data, it is noted in 
about 5–10% of patients treated with a single ICI 
agent, but is more commonly seen (nearly 20%) 
with combination therapies.39,40
Figure 2. (a) A case of ipilimumab-related colitis. A patient with melanoma was treated with ipilimumab 
(anti- CTLA-4). Severe active colitis, with expansion of lamina propria lymphoplasma cells, cryptitis, 
crypt destruction/dropout and crypt architecture alteration. (b) Additionally, many crypts show significant 
distention (‘ballooning’) due to intraluminal inflammatory exudate accumulation. (c) A male patient was given 
ipilimumab, nivolumab and IL2 to treat metastatic prostatic carcinoma, then developed bloody diarrhoea. 
Severe active chronic colitis mimics ulcerative colitis. (d) Severe active colitis, with expansion of lamina propria 
lymphoplasma cells, cryptitis, crypt abscesses, crypt destruction/dropout, crypt architecture alteration and 
basal lymphoplasmacytosis.
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The rise in liver enzyme levels is asymptomatic 
unless accompanied by a significant rise in biliru-
bin causing jaundice, which is rare. The condition 
is usually picked up on routine blood tests. The 
rise in enzyme levels appears to be significantly 
high, starting at about 6 weeks after initiation of 
therapy, and the risk appears to be sustained up 
to 14 weeks after the drug is given.
Patients who have documented high transami-
nases should be monitored closely. They should 
have investigations in keeping with the general 
principles of testing for liver disease. A full nonin-
vasive liver screen including for viral hepatitis 
[hepatitis A, B and C viruses, Epstein–Barr virus 
(EBV), cytomegalovirus (CMV) and varicella 
zoster virus], an autoimmune screen which 
includes antinuclear antibodies, anti-cytoplasmic 
antibodies, anti-mitochondrial antibodies and 
anti-smooth muscle antibodies should be com-
pleted. An ultrasound of the liver is mandatory, 
and getting a portal vein Doppler to rule out a 
thrombus would be prudent in view of the 
increased thrombosis risk due to malignancy. Any 
positive tests from the above panel should prompt 
appropriate further investigations. If negative, 
patients can be treated as per guidance for ICI-
related hepatotoxicity, which is discussed in more 
detail in a separate section.
In rare cases, a liver biopsy may be indicated, but 
this has to be carefully considered in select patients, 
given the significant risk and relatively low benefit. 
Histologically, the ICI-related hepatotoxicity is 
commonly hepatitis and is characterized by pre-
dominantly lobular inflammation with milder por-
tal inflammation. The infiltrating inflammatory 
cells are largely CD3+/CD8+ T cells. Bile duct 
injury is rare and very mild if present.41 Anti-
CTLA-4 related hepatitis is also often associated 
with nonnecrotizing granulomas.42
Management
Management of GI AEs
There are a number of suggested management 
algorithms based on the severity of diarrhoea. 
There is one recent proposed treatment algorithm 
that suggests managing the ICI-related AE based 
on the type of immune infiltrate noted in the 
affected organ and drawing from experience in 
other autoimmune conditions.43 Although this is 
a very reasonable approach, in clinical practice 
the distinction in infiltrates may not always be 
clear enough to guide treatment decisions. We 
propose a simple and effective algorithm that is 
guided by clinical symptoms and supported by 
endoscopic appearance and imaging (Figure 3).
Management of mild diarrhoea (bowels open 
<4 times per day) is generally supportive. 
Budesonide can be considered as an oral corticos-
teroid. For moderate colitis (bowels open 
4–6 times per day) treatment with prednisolone 
0.5–1.0 mg/kg/day is recommended. Patients with 
severe diarrhoea (bowels opened >6 times per 
day) should ideally be commenced on intrave-
nous corticosteroids (methylprednisolone 1–2 mg/
kg/day), and in steroid-responsive patients this 
should be followed by a tapering course of oral 
prednisolone over 6–8 weeks. There are currently 
no predictive markers to determine nonresponse 
to corticosteroid therapy.
Steroid-refractory patients (nonresponse to intra-
venous corticosteroids after 72 h) require treat-
ment with anti-TNF therapy. Infliximab has been 
used successfully in this setting with a dosing regi-
men similar to that in IBD, starting with an initial 
dose of 5 mg/kg.44 A further dose may be required 
after 2 weeks. Following response to infliximab, 
prolonged therapy with a tapering course of oral 
prednisolone may be necessary and a subgroup of 
patients may develop steroid-dependent disease. 
Johnson and colleagues evaluated the effect of 
early use of infliximab for ICI-related colitis.45 
The authors noted that patients who received inf-
liximab and steroids combined had significantly 
shorter times to resolution of diarrhoea (median 
3 days versus 9 days; p < 0.001) and steroid titra-
tion (median 4 days versus 13 days; p < 0.001) 
compared to patients who were given corticoster-
oids alone. Among patients receiving combined 
infliximab and steroids, the majority (86%) had 
documented grade 3/4 colitis. It was also noted 
that there was no increased risk of failure of the 
ICI therapy in patients exposed to infliximab and 
the overall survival was greater in the group 
receiving combined infliximab and steroids after a 
median follow up of 26 months.45
There is now emerging evidence that the anti-
integrin antibody, vedolizumab, is also an effec-
tive option. A case report first showed the efficacy 
of vedolizumab in the setting of steroid-depend-
ent ipilimumab-associated colitis.46 Another 
study recently published in 2018 reported the 
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Figure 3. Proposed algorithm for management of checkpoint inhibitor-associated diarrhoea or colitis.
CMV, cytomegalovirus; CT, computed tomography; ICI, immune checkpoint inhibitors; IV, intravenous.
outcomes of vedolizumab use in patients with 
ICI-related colitis.47 A retrospective review of 28 
patients who received vedolizumab for steroid-
refractory disease showed that 24 achieved clini-
cal remission, with mean duration of follow up of 
15 months (Table 3). It is worth mentioning that 
in this cohort, although patients who had not 
received infliximab prior to vedolizumab therapy 
had a higher success rate (95%), the success rate 
among patients exposed to infliximab remained 
as high as 67%. Figure 3 is a proposed algorithm 
to manage patients with or without multisystem 
involvement.
There is a theoretical concern that immunosup-
pressive therapy may compromise the anti-
tumour response to checkpoint inhibitor therapy. 
Systemic corticosteroids do not appear to affect 
the response rates to ipilimumab or nivolumab; 
however, the effect of other immunosuppressive 
therapy such as infliximab remains unclear.52,53
ICI therapy should be interrupted on develop-
ment of colitis and permanent discontinuation is 
recommended for episodes that progress to 
severe or life-threatening stages, classified as 
grade 3 or 4 according to the National Cancer 
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Institute’s Common Terminology (NCI 
CTCAE) criteria.4 In other cases, reintroduction 
can be cautiously considered on a case-by-case 
basis. A retrospective study suggested that anti-
PD-1 therapy can be administered safely in 
patients who previously experienced grade 3 or 4 
colitis with ipilimumab.54 At present there are no 
data supporting prophylactic corticosteroid ther-
apy for IrAEs.55
Faecal microbiota transplant (FMT) has recently 
been used for ICI-related colitis and early reports 
from a case series of two patients treated with 
FMT appear encouraging.48 FMT resulted in 
complete resolution of symptoms followed by 
improvement in endoscopic appearances (Table 3). 
This is very early work and more data and evi-
dence is required in this area before this can be 
recommended.
Table 3. Summary of studies of ICI-related GI and liver complications refractory to steroids.
Therapy for ICI-
related colitis
Study Dosages used Results
Infliximab Johnson et al.45
Compared infliximab 
versus corticosteroids
(75 patients, 48% received 
infliximab)
1–3 infusions of infliximab •   Infliximab + steroids superior to steroids 
alone
•   Resolution of diarrhoea 3 days versus 
9 days (median)
•   Duration of steroid use shorter at 35 days 
versus 51 days (median)
Pagès et al.44
(case report of one patient)
Infliximab (5 mg/kg) single 
dose
•  Symptom resolution in 2 days
•   Mucosal healing on endoscopy noted on 
day 7
Vedolizumab Hsieh et al.46
(case report of one patient)
Standard induction dose 
(300 mg at 0, 2 and 6 weeks)
•  Resolution of symptoms in 6 weeks
•  Successfully weaned off steroids
•  Mucosal healing on endoscopy by 6 weeks
Abu-Sbeih et al.47
(28 patients)
3 infusions of vedolizumab •   Duration for improvement in symptoms 
after vedolizumab was 5 days (median)
•   Sustained clinical remission in 84% of 
patients
Faecal microbial 
transplant
Wang et al.48
(case report of two 
patients)
FMT delivered via 
colonoscopy (50 g/250 ml) of 
liquid donor stool
•   Clinical improvement with one patient but 
patient died after 3 months due to primary 
malignancy
•   Sustained remission after 7 months of 
treatment with second patient
Therapy for ICI-
related hepatic 
complications
Mycophenolate 
mofetil
Tanaka et al.49
(case report of one patient)
2 g/day in addition to 
steroids (2 g for about 
6 weeks and then tapered 
down and stopped in 
2 weeks)
•   Improvement in both AST and ALT with no 
recurrence after stopping MMF therapy
Anti-thymocyte 
globulin
Chmiel et al.50
(case report of one patient)
1.5 mg/kg over 2 consecutive 
days followed by 2 doses 
over next 2 weeks
•   Reduction in transaminases within 24 h 
and was sustained
Toclizumab Stroud et al.51
(39 patients received 
toclizumab but included 
other indications)
4 mg/kg infusion over 1 h
Multiple infusions as per 
clinician decision
•   Clinical improvement reported in 79% of 
patients but no specific data on hepatitis 
only
ICI, immune checkpoint inhibitors; GI, gastrointestinal; MMF, Mycophenolate mofetil. 
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A summary of therapies currently used, relevant 
studies regarding the same and the dose regimes 
used in these studies are listed in Table 3.
Management of hepatic dysfunction
The standard management of grade 1–2 hepatic 
dysfunction is generally in the form of closer mon-
itoring to ensure that worsening liver tests towards 
a grade 3–4 AE are picked up early on.9 The man-
agement of grades 3–4 liver toxicity requires high-
dose intravenous glucocorticoids for 24–48 h, 
followed by an oral steroid taper with predniso-
lone at 1–2 mg/kg over at least a period of 30 days.9 
It is safer to withhold immunotherapy until the 
liver function tests return to at least grade 1.10 Any 
derangement beyond eight times the upper limit 
of normal should be measured three times per 
week until an improving trend is noticed.
During the course of treatment, if there is no 
improvement or there is a worsening trend of liver 
function tests within 48 h of systemic steroids, 
mycophenolate mofetil 500 mg every 12 h should 
be considered.49 In refractory cases, anti-thymocyte 
globulin can be tried at a dose of 1.5 g/kg for 48 h, 
which has been reported to be successful in a 
patient who developed ipilimumab-related liver 
toxicity.50 There is one study where anti IL-6 
antibody toclizumab was used to manage all 
IrAEs, including hepatitis.51 There was clinical 
improvement in nearly 80% of patients (Table 4).
ICI-related hepatitis may take up to 3 months to 
resolve completely after withdrawal of the offend-
ing drug.
Predicting GI and hepatic AEs. It has been sug-
gested that intrinsic patient factors may be 
responsible for IrAEs and this could possibly be 
identified by identification of genetic, epigenetic 
or other predictive markers.43
There are patient factors – for example, female 
sex, baseline sarcopenia, concurrent medications 
– that have been identified as affecting outcomes 
and severity of ICI-related toxicity; some bio-
markers, such as T cell population, increased 
eosinophil counts, increased IL-17 levels, reduced 
circulating IL-6 levels and gut microbiome, have 
been shown to predict ICI-related AEs.56–58 In 
one study reported by Chaput and colleagues, it 
was noted that patients with melanoma who had 
baseline microbiota enriched with the 
Faecalibaterium genus and other Firmicutes had 
higher incidence of ICI-related colitis when 
exposed to ipilimumab; on the other hand, it was 
also noted that patients who had Bacteroidetes 
remained free of ICI-related colitis.59 These find-
ings may be useful in predicting IrAEs in the 
future, but more studies are needed before this is 
used routinely.
In another study published by Friedlander and 
colleagues in 2018, the group retrospectively 
looked at gene signatures from patients on treme-
limumab in a clinical trial to see if there are any 
predictive markers of ICI-related IrAEs in patients 
with melanoma.60 Peripheral blood gene expres-
sion signatures were checked pre- and post- 
treatment for patients who had documented GI 
toxicity. In the pre-treatment data, no gene signifi-
cantly predicted development of grade 2 or higher 
Table 4. Management of hepatitis related to ICI therapy.
Grade 1–2 hepatitis Grade 3 hepatitis Grade 4 hepatitis
Criteria AST or ALT 1–
2.5 × ULN and/or total 
bilirubin 1–1.5 × ULN
AST or ALT >5 × ULN and/or total 
bilirubin >3 × ULN
AST or ALT >8 × ULN
ICI therapy Continue but with close 
monitoring
Discontinue Discontinue
Steroids Consider oral steroids High-dose IV steroids for 48 h and 
taper with oral steroids
High-dose IV steroids
Other drugs 
to consider
None at this stage •   Mycophenolate mofetil 500 mg 
BD if no improvement after 48 h 
of steroids
•   Longer duration of high-dose IV steroids
•   Anti-thymocyte globulin
•  Toclizumab (anti IL-6 antibody)
BD, twice daily; IV, intravenous; ULN- upper limit of normal. 
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colitis, but they identified a 16-gene signature that 
probably could distinguish onset of severe versus 
mild or no diarrhoea. The gene signature dataset 
was validated in another tremelimumab clinical 
trial at a later date. Out of the 16-gene signature, 
six were found to be predictive – CCL3, CCR3, 
IL5, IL8, PTGS2, GADD45A – and were seen to 
be upregulated in patients with toxicity.60
Conclusion
ICI therapy has led to a paradigm shift in oncol-
ogy. The IrAEs due to ICI are common and with 
their increasing use it is imperative that clinicians 
recognize these early and initiate prompt treat-
ments. Immune-related colitis and hepatitis are 
likely to be encountered more frequently by gas-
troenterologists, who will need to be aware of 
these AEs in order to manage patients safely and 
effectively. Early recognition and treatment are 
critical as the majority of patients who are man-
aged appropriately show good clinical response, 
go into remission and have fewer serious compli-
cations. Based on current evidence, early aggres-
sive management of colitis with steroids and 
biologics like infliximab or vedolizumab appears 
to be beneficial, with good success rates. In refrac-
tory colitis, FMT is an emerging option although 
more studies are required to establish its efficacy 
and safety. Immune-mediated hepatitis requires 
close monitoring and sometimes temporary with-
drawal of ICI in severe cases, but overall the 
response to steroids appears to be good.
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